This single arm study will assess the efficacy and safety of sequential neoadjuvant chemotherapy and Avastin, before surgery and/or radiotherapy, in patients with inflammatory or locally advanced operable breast cancer. Patients will receive FEC, followed by paclitaxel, given concomitantly with Avastin (10mg/kg i.v. every 2 weeks). The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals.